New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
04:55 EDTILMN, ILMN, AET, AET, AMGN, AMGN, NVS, NVS, ECYT, ECYT, CELG, CELG, LIFE, LIFE, OMED, OMED, MRK, MRK, CERN, CERN, TROV, TROV, UNH, UNHPersonalized Medicine World Conference to hold a conference
PMWC 2014 Silicon Valley is being held in Mountain View, California on January 26-28.
News For ILMN;TROV;CERN;MRK;OMED;LIFE;CELG;ECYT;NVS;AMGN;AET;UNH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
January 20, 2015
12:51 EDTCERNCerner loss of Mayo opportunity likely to have little impact, says Deutsche Bank
Subscribe for More Information
12:39 EDTCERNCerner slips after report of losing Mayo pact to Epic
Subscribe for More Information
11:24 EDTILMNIllumina could see headline boost from U.S. genomics project, says Wells Fargo
After biotech industry publication BioCentury said Friday that the president may announce a new genomics project to sequence up to one million human genomes as part of his State of the Union speech tonight, Wells Fargo said that it believes such an announcement could be a headline catalyst for Illumina since it would mean the U.S. needs additional sequencing capacity. However, such a project would be long-term in nature, Wells Fargo cautioned, adding that such a plan would more likely support existing Illumina growth assumptions than push those forecasts up. Shares of Illumina are up 6% to $194.85 in morning trading ahead of tonight's speech by the president.
08:18 EDTTROVTrovagene says study results support utility of cancer monitoring platform
Subscribe for More Information
07:23 EDTMRKMerck funding testing of lower dosages of Zilmax, Reuters reports
Subscribe for More Information
January 18, 2015
17:40 EDTAETAetna customers can switch coverage after mistake, Bloomberg says
Aetna is being investigated by the U.S. for misleading elderly and disabled people about which pharmacies would fill prescriptions in Medicare drug plans the health insurer sold them, says Bloomberg. According to the Bloomberg report, customers will be able to quit their coverage and choose a new plan this year as a result. Raymond Thorn, a spokesman for the Centers for Medicare and Medicaid Services said Aetna may be fined or prohibited from enrolling new Medicare customers if the agency determines it intentionally misled Medicare patients, added Bloomberg. Reference Link
January 16, 2015
14:54 EDTAETGilead at high of day, up 3% after reaching hep C drug pact with Aetna
14:46 EDTAETAetna, Gilead confirm discount pricing for hepatitis C drugs Harvoni, Sovaldi
Subscribe for More Information
14:33 EDTOMEDOncoMed presents final Phase 1b data for Tarextumab
OncoMed Pharmaceuticals presented final safety, efficacy and biomarker data from the company's Phase 1b "ALPINE" clinical trial of tarextumab in 40 patients with frontline metastatic pancreatic cancer. Tarextumab was generally well tolerated when administered with gemcitabine and Abraxane, with manageable, on-target drug-related toxicities. The Phase 2 dose of tarextumab was determined to be 15 mg/kg every two weeks in combination with the standard-of-care. Among patients evaluable for response using RECIST criteria, 38% achieved partial responses, with an additional 35% achieving stable disease for an overall clinical benefit rate of 73%. Median progression-free survival and overall survival values for the three drug combination of tarextumab-gemcitabine-Abraxane were 5.6 months and 11.6 months, respectively, for all patients treated with the three-drug combination. The data presented included biomarker analyses that showed that among patients whose tumor samples had elevated levels of Notch3 gene expression, trends toward higher response rates and longer survival were noted, as compared to patients with low Notch3 expression. Median PFS and OS for patients with high Notch 3 expression were 6.6 months and 14.6 months, respectively. Given the small sample size and potential imbalances in patient characteristics, these encouraging preliminary efficacy and predictive biomarker observations are being assessed in the ongoing randomized, placebo-controlled, Phase 2 ALPINE trial
10:47 EDTUNH, AETBofA/Merrill healthcare facilities analyst analyst/industry conference call
Healthcare Facilities & Managed Care Analyst Bressler discusses the legislative and regulatory outlook for the industry for 2015 on an Analyst/Industry conference call to be held on January 23 at 2 pm.
09:11 EDTCELGCelgene says oral Otezla approved by European Commission in 2 indications
Celgene International, a wholly-owned subsidiary of Celgene Corporation, announced that the European Commission has granted marketing authorisation for OTEZLA, the company’s oral selective inhibitor of phosphodiesterase 4, in two therapeutic indications: For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light. Alone or in combination with Disease Modifying Antirheumatic Drugs, for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy. The marketing authorization is based on efficacy and safety data from two Phase III programs, ESTEEM AND PALACE, which demonstrate a maintained clinical response among patients with psoriasis and psoriatic arthritis treated with OTEZLA through 52 weeks, across multiple endpoints. The EC decision follows the positive opinion issued by the Committee for Medicinal Products for Human Use in November 2014.12 OTEZLA will be launched in the European Union in the coming months in accordance with local requirements.
08:31 EDTNVSGlaxoSmithKline CEO says more IPOs like ViiV could happen, Retuers says
Subscribe for More Information
January 15, 2015
16:04 EDTAMGNAmgen announces new data from Phase 2 PEAK, Phase 3 PRIME studies
Amgen announced new data from the Phase 2 PEAK and Phase 3 PRIME studies that support the first-line use of Vectibix in combination with Folfox, an oxaliplatin-based chemotherapy regimen, in patients with wild-type RAS metastatic colorectal cancer. In an exploratory analysis from the PEAK study, treatment with Vectibix compared to Avastin resulted in a "significantly higher proportion" of patients with earlier tumor shrinkage at week eight, 64% vs. 45%, respectively, and among responding patients, a longer duration of response, 11.4 vs. 8.5 months, respectively, and greater depth of response . Overall response rates appeared to be similar between Vectibix and Avastin. This is consistent with observed overall survival and progression-free survival (PFS) rates, and with data previously reported, Amgen said. It added, "While the primary analysis from PEAK showed similar ORR between the Vectibix- and bevacizumab-based regimens, this exploratory analysis demonstrates that Vectibix produces early, sustained anti-tumor activity, which may in part explain the OS and PFS benefits seen with Vectibix versus bevacizumab in this trial."
13:10 EDTUNHUnitedHealth volatility elevated into Q4 and outlook
Subscribe for More Information
11:20 EDTMRKGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
08:36 EDTOMEDOncoMed enrolls first biomarker-selected patient in Notch1 antibody Phase trial
Subscribe for More Information
08:31 EDTUNHUnitedHealth, ProHEALTH announce new collaboration agreement
Subscribe for More Information
07:59 EDTMRK, CELG, TROV, AMGNAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information
January 14, 2015
11:45 EDTNVSImmunoGen discloses triggering of $5M milestone payment from Novartis
Subscribe for More Information
08:34 EDTMRKMerck and Practice Fusion's health vaccine initiative shows positive results
Merck and Practice Fusion announced the results of a recent collaboration designed to improve public health outcomes through a Population Health Management program for adult vaccines. Launched in April, the program contributed to a statistically significant relative increase in recorded vaccinations among eligible patients on Practice Fusion's EHR platform. During the four-month test period, Practice Fusion observed a 73% relative increase in recorded vaccinations in test versus control patients.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use